Exploring designability of electrostatic complementarity at an antigen-antibody interface directed by mutagenesis, biophysical analysis, and molecular dynamics simulations.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 03 2019
Historique:
received: 07 09 2018
accepted: 08 02 2019
entrez: 16 3 2019
pubmed: 16 3 2019
medline: 2 10 2020
Statut: epublish

Résumé

Antibodies protect organisms from a huge variety of foreign antigens. Antibody diversity originates from both genetic and structural levels. Antigen recognition relies on complementarity between antigen-antibody interfaces. Recent methodological advances in structural biology and the accompanying rapid increase of the number of crystal structures of proteins have enabled atomic-level manipulation of protein structures to effect alterations in function. In this study, we explored the designability of electrostatic complementarity at an antigen-antibody interface on the basis of a crystal structure of the complex. We designed several variants with altered charged residues at the interface and characterized the designed variants by surface plasmon resonance, circular dichroism, differential scanning calorimetry, and molecular dynamics simulations. Both successes and failures of the structure-based design are discussed. The variants that compensate electrostatic interactions can restore the interface complementarity, enabling the cognate antigen-antibody binding. Retrospectively, we also show that these mutational effects could be predicted by the simulations. Our study demonstrates the importance of charged residues on the physical properties of this antigen-antibody interaction and suggests that computational approaches can facilitate design of antibodies that recognize a weakly immunogenic antigen.

Identifiants

pubmed: 30872635
doi: 10.1038/s41598-019-40461-5
pii: 10.1038/s41598-019-40461-5
pmc: PMC6418251
doi:

Substances chimiques

Antibodies 0
Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4482

Références

Sci Transl Med. 2011 May 25;3(84):84ra44
pubmed: 21613623
Sci Rep. 2013 Nov 20;3:3271
pubmed: 24253561
J Biochem. 2015 Jul;158(1):1-13
pubmed: 25956164
J Mol Biol. 1997 May 2;268(2):570-84
pubmed: 9159491
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Proteins. 2003 Jul 1;52(1):2-9
pubmed: 12784359
Chem Biol. 2012 Apr 20;19(4):449-55
pubmed: 22520751
PLoS One. 2014 Jan 27;9(1):e87099
pubmed: 24475232
Proteins. 2011 Mar;79(3):821-9
pubmed: 21287614
Curr Opin Struct Biol. 2015 Aug;33:27-41
pubmed: 26188469
J Mol Biol. 1997 Nov 7;273(4):882-97
pubmed: 9367779
Biophys J. 2002 Dec;83(6):2946-68
pubmed: 12496069
Essays Biochem. 2016 Jun 30;60(1):9-18
pubmed: 27365031
Bioinformatics. 2016 Aug 15;32(16):2451-6
pubmed: 27153634
Nat Struct Biol. 2003 Dec;10(12):980
pubmed: 14634627
Curr Opin Biotechnol. 1997 Feb 1;8(1):50-7
pubmed: 9013659
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nat Biotechnol. 2007 Oct;25(10):1171-6
pubmed: 17891135
Front Mol Biosci. 2015 Oct 13;2:56
pubmed: 26528483
J Chem Inf Model. 2013 Nov 25;53(11):2937-50
pubmed: 24168661
BMC Med. 2016 May 05;14:73
pubmed: 27151159
J Immunol. 2010 Oct 1;185(7):4199-205
pubmed: 20817878
J Comput Chem. 2008 Aug;29(11):1859-65
pubmed: 18351591
Protein Eng Des Sel. 2012 Oct;25(10):507-21
pubmed: 22661385
Proteins. 2004 Jul 1;56(1):130-42
pubmed: 15162493
Blood Transfus. 2007 Nov;5(4):227-40
pubmed: 19204779
Protein Eng Des Sel. 2006 Sep;19(9):421-9
pubmed: 16837482
Biochemistry. 1981 May 26;20(11):3096-102
pubmed: 7248271
J Mol Biol. 1993 Dec 20;234(4):946-50
pubmed: 8263940
Biotechnol Prog. 2004 Sep-Oct;20(5):1301-8
pubmed: 15458311
Anal Biochem. 1991 Nov 1;198(2):268-77
pubmed: 1724720
J Am Chem Soc. 2007 Aug 22;129(33):10110-2
pubmed: 17665911
Front Immunol. 2013 Oct 08;4:302
pubmed: 24115948
Protein Eng Des Sel. 2013 Dec;26(12):773-80
pubmed: 24214686
J Am Chem Soc. 2004 Jan 28;126(3):698-9
pubmed: 14733527
J Mol Biol. 2017 Apr 7;429(7):930-947
pubmed: 27908641
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658

Auteurs

Kouhei Yoshida (K)

Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.

Daisuke Kuroda (D)

Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
Medical Device Development and Regulation Research Center, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.

Masato Kiyoshi (M)

The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Makoto Nakakido (M)

Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.

Satoru Nagatoishi (S)

Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan.
The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Shinji Soga (S)

Modality Research Laboratories, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.

Hiroki Shirai (H)

Modality Research Laboratories, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.

Kouhei Tsumoto (K)

Department of Bioengineering, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. tsumoto@bioeng.t.u-tokyo.ac.jp.
Medical Device Development and Regulation Research Center, School of Engineering, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8656, Japan. tsumoto@bioeng.t.u-tokyo.ac.jp.
The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. tsumoto@bioeng.t.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH